1. Australia Stocks

  2. •

    Non-energy minerals

  3. •

    Other metals/Minerals
EchoIQ Limited

EchoIQ Limited

0.46
AUD
+0.04
(+9.64%)
-0.03EPS
1.05BMarket Cap
Mar 04Next Earn
EchoIQ Limited
ASX:EIQ
(Australian Securities Exchange)

Recent

price

0.46

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
AUD
- -
- -
- -
- -
- -
- -
- -
- -
0.01
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-0.48
-0.31
-0.11
-0.1
-0.2
-0.31
-0.45
-0.04
-0.01
-0.01
-0.01
-0.01
-0.02
-0.01
- -
-0.03
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.94
0.62
0.51
0.36
0.24
0.01
0.02
- -
-0.01
0.01
0.02
0.02
0.02
0.01
- -
0.02
Book Value per Share
0.94
0.62
0.51
0.36
0.24
0.01
0.02
- -
-0.01
0.01
0.01
- -
- -
- -
- -
0.01
Tangible Book Value per Share
2
4
3
5
8
10
32
36
70
225
294
393
448
455
567
653
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
-1,360.36
-18,146.68
-43.55
-382.89
-318.92
-2,489.23
-7,150.58
-14,834.37
- -
-21,573.91
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
- -
1
Depreciation Expense
-1
-1
- -
-1
-2
-3
-14
-2
-1
-3
-3
-6
-8
-5
- -
-19
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
-9,861.54
-10,505.43
-63.94
-400.46
-303.1
-2,259.45
-7,270.29
-12,155.38
- -
-20,180.43
Profit Margin (%)
3
1
- -
- -
- -
- -
1
- -
-1
2
3
- -
1
- -
- -
7
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
3
2
2
3
2
- -
- -
- -
-1
3
9
8
7
7
- -
12
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-42.09
-19.71
-24.63
-72.45
-274.39
-5,582.94
- -
- -
- -
-47.87
-66.13
-102.17
-76.17
- -
- -
Return on Common Equity (%)

Capital Structure

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

AUD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Earnings Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.01
2025
- -
- -
- -
2026
- -
- -
-0.03

Semi-annual Dividends Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Similar Companies
MP Materials Corp. (NYSE:MP)
Energy Fuels Inc (AMEX:UUUU)
Freeport-McMoRan, Inc. (NYSE:FCX)
Hindalco Industries Limited (NSE:HINDALCO)
Cameco Corporation (NYSE:CCJ)
Uranium Energy Corp. (AMEX:UEC)
Business
Echo IQ Limited is a medical technology company specializing in artificial intelligence solutions for cardiovascular diagnostics, operating from its base in Sydney, Australia. The company develops the advanced EchoSolv™ platform, which employs AI-driven analysis of echocardiographic data to significantly improve the identification and risk stratification of structural heart conditions such as aortic stenosis, diastolic dysfunction, and heart failure. This innovative technology assists medical professionals in making more precise and timely decisions for improved patient care. Echo IQ serves a broad range of healthcare providers, including physicians, hospitals, and health systems across Australia and the United States. The company’s revenue model is primarily software-as-a-service, incorporating per-scan payments and strategic licensing agreements. Key recent developments include securing FDA clearance for its EchoSolv-AS product in October 2024, enabling wider commercialization in the US market, and a substantial A$7.1 million institutional placement in September 2024 to support ongoing expansion and product development. Echo IQ has also forged significant partnerships with US healthcare technology providers like ScImage, MedAxiom, and SARC MedIQ to integrate its AI solutions across extensive cardiology networks. The company leverages exclusive access to a vast, de-identified cardiac data repository, critical for training its highly accurate AI algorithms that have demonstrated superior detection rates for serious heart conditions in clinical studies.

Company News

Company News APIChatGPT

  • globenewswire.com

    Echo IQ to Present at the Life Sciences Virtual Investor Forum on 11th December

  • globenewswire.com

    Echo IQ to Participate in the Piper Sandler 37th Annual Healthcare Conference